Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 Jun 28

PMID 37371567

Authors

Shan Li

Juan Li

Wenjing Shi

Ziyan Nie

Shasha Zhang

Fengdie Ma

Jun Hu

Jianjun Chen

Peiqiang Li

Xiaodong Xie

Affiliations

Soon will be listed here.

Abstract

Around 11% of all known gene lesions causing human genetic diseases are nonsense mutations that introduce a premature stop codon (PTC) into the protein-coding gene sequence. Drug-induced PTC readthrough is a promising therapeutic strategy for treating hereditary diseases caused by nonsense mutations. To date, it has been found that more than 50 small-molecular compounds can promote PTC readthrough, known as translational readthrough-inducing drugs (TRIDs), and can be divided into two major categories: aminoglycosides and non-aminoglycosides. This review summarizes the pharmacodynamics and clinical application potential of the main TRIDs discovered so far, especially some newly discovered TRIDs in the past decade. The discovery of these TRIDs brings hope for treating nonsense mutations in various genetic diseases. Further research is still needed to deeply understand the mechanism of eukaryotic cell termination and drug-induced PTC readthrough so that patients can achieve the greatest benefit from the various TRID treatments.

Citing Articles

Engineered tRNAs efficiently suppress CDKL5 premature termination codons.

Pezzini S, Mustaccia A, Aboa P, Faustini G, Branchini A, Pinotti M Sci Rep. 2024; 14(1):31791.

PMID: 39738338 PMC: 11685654. DOI: 10.1038/s41598-024-82766-0.

Misincorporations of amino acids in p53 in human cells at artificially constructed termination codons in the presence of the aminoglycoside Gentamicin.

Pawlicka K, Henek T, Uhrik L, Hernychova L, Padariya M, Faktor J Front Genet. 2024; 15:1407375.

PMID: 39563734 PMC: 11573534. DOI: 10.3389/fgene.2024.1407375.

Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa.

Levian B, Hou Y, Tang X, Bainvoll L, Zheng K, Badarinarayana V Mol Ther Nucleic Acids. 2024; 35(4):102334.

PMID: 39391765 PMC: 11465179. DOI: 10.1016/j.omtn.2024.102334.

Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms.

Torices L, Nunes-Xavier C, Pulido R Cancers (Basel). 2024; 16(16).

PMID: 39199607 PMC: 11352852. DOI: 10.3390/cancers16162836.

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules.

Toledano I, Supek F, Lehner B Nat Genet. 2024; 56(9):1914-1924.

PMID: 39174735 PMC: 11387191. DOI: 10.1038/s41588-024-01878-5.

References

Guy M, Shaw M, Weiner C, Hobson L, Stark Z, Rose K . Defects in tRNA Anticodon Loop 2'-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability due to Mutations in FTSJ1. Hum Mutat. 2015; 36(12):1176-87. PMC: 4643400. DOI: 10.1002/humu.22897. View

Leubitz A, Frydman-Marom A, Sharpe N, van Duzer J, Campbell K, Vanhoutte F . Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019; 8(8):984-994. DOI: 10.1002/cpdd.647. View

Chang C, Hui Y, Elchert B, Wang J, Li J, Rai R . Pyranmycins, a novel class of aminoglycosides with improved acid stability: the SAR of D-pyranoses on ring III of pyranmycin. Org Lett. 2002; 4(26):4603-6. DOI: 10.1021/ol0269042. View

Du L, Jung M, Damoiseaux R, Completo G, Fike F, Ku J . A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther. 2013; 21(9):1653-60. PMC: 3776636. DOI: 10.1038/mt.2013.150. View

Sabbavarapu N, Shavit M, Degani Y, Smolkin B, Belakhov V, Baasov T . Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations. ACS Med Chem Lett. 2016; 7(4):418-23. PMC: 4834649. DOI: 10.1021/acsmedchemlett.6b00006. View

Schroeder S, Blaha G, Moore P . Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit. Antimicrob Agents Chemother. 2007; 51(12):4462-5. PMC: 2167971. DOI: 10.1128/AAC.00455-07. View

Ferguson M, Gerak C, Chow C, Rastelli E, Elmore K, Stahl F . The antimalarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418. PLoS One. 2019; 14(5):e0216423. PMC: 6532957. DOI: 10.1371/journal.pone.0216423. View

Baradaran-Heravi A, Balgi A, Hosseini-Farahabadi S, Choi K, Has C, Roberge M . Effect of small molecule eRF3 degraders on premature termination codon readthrough. Nucleic Acids Res. 2021; 49(7):3692-3708. PMC: 8053119. DOI: 10.1093/nar/gkab194. View

Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K . Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012; 7:58. PMC: 3562214. DOI: 10.1186/1750-1172-7-58. View

10.

Li Y, Yu X, Pan C, Wang Y, Han J, Yao Z . Effect of Gentamicin Ointment in Patients with Nagashima-type Palmoplantar Keratosis: A Double-blind Vehicle-controlled Study. Acta Derm Venereol. 2021; 101(2):adv00392. PMC: 9366704. DOI: 10.2340/00015555-3760. View

11.

Du M, Jones J, Lanier J, Keeling K, Lindsey J, Tousson A . Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl). 2002; 80(9):595-604. DOI: 10.1007/s00109-002-0363-1. View

12.

Mosallaei D, Hao M, Antaya R, Levian B, Kwong A, Cogan J . Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. JAMA Dermatol. 2022; 158(4):366-374. PMC: 8892363. DOI: 10.1001/jamadermatol.2021.5992. View

13.

Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J . A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun. 2021; 12(1):4358. PMC: 8285393. DOI: 10.1038/s41467-021-24575-x. View

14.

Kuang L, Hashimoto K, Huang E, Gentry M, Zhu H . Frontotemporal dementia non-sense mutation of progranulin rescued by aminoglycosides. Hum Mol Genet. 2020; 29(4):624-634. PMC: 7068117. DOI: 10.1093/hmg/ddz280. View

15.

Friesen W, Trotta C, Tomizawa Y, Zhuo J, Johnson B, Sierra J . The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA. 2017; 23(4):567-577. PMC: 5340919. DOI: 10.1261/rna.060236.116. View

16.

Shiozuka M, Wagatsuma A, Kawamoto T, Sasaki H, Shimada K, Takahashi Y . Transdermal delivery of a readthrough-inducing drug: a new approach of gentamicin administration for the treatment of nonsense mutation-mediated disorders. J Biochem. 2009; 147(4):463-70. DOI: 10.1093/jb/mvp185. View

17.

Kosmidis G, Veerman C, Casini S, Verkerk A, van de Pas S, Bellin M . Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Nav1.5 Function of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A. Circ Arrhythm Electrophysiol. 2016; 9(11). DOI: 10.1161/CIRCEP.116.004227. View

18.

Bidou L, Bugaud O, Belakhov V, Baasov T, Namy O . Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 2017; 14(3):378-388. PMC: 5367250. DOI: 10.1080/15476286.2017.1285480. View

19.

Grem J . 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000; 18(4):299-313. DOI: 10.1023/a:1006416410198. View

20.

Reeves E, Dunlea D, McQuillan K, ODwyer C, Carroll T, Saldova R . Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity. J Immunol. 2019; 202(8):2240-2253. PMC: 6452030. DOI: 10.4049/jimmunol.1801045. View